Experts from IQVIA’s Pharma Pricing & Reimbursement and Market Prognosis teams provide an update on the outlook for “off-year” price revisions in Japan.
Original (December 2020) Article:
WADING INTO THE ONGOING DEBATE OVER PLANS TO CARRY OUT AN ‘OFF-YEAR’ REVISION IN 2021 OF NATIONAL HEALTH INSURANCE (NHI) REIMBURSEMENT PRICES FOR PRESCRIPTION MEDICINES, NEW PRIME MINISTER (PM) YOSHIHIDE SUGA IS REPORTED TO HAVE STRONGLY BACKED THE PROPOSALS, DESPITE ONGOING RESISTANCE FROM THE MEDICINES INDUSTRY. AND WHILE THE MINISTRY OF HEALTH, LABOUR AND WELFARE (KOROSHO) HAS YET TO MAKE A FINAL DECISION ON THE MATTER, WITH OTHER STAKEHOLDERS – INCLUDING THE MINISTRY OF FINANCE (MOF) – URGING AN EVEN TOUGHER STANCE ON DRUG PRICES, FEW WOULD BET AGAINST THE PRICE ADJUSTMENTS GOING AHEAD NEXT YEAR.
The debate over ‘off-year’ price revisions has its roots in proposals set out by the government in late 2016 and formalised by Korosho in late 2017. Under the proposals, the Ministry plans to complement the existing biennial price revision process (under which prices for all reimbursed medicines are adjusted every two years – most recently in April 2020) with a separate process that would review the NHI reimbursement prices of certain medicines in the ‘off-year’ between each biennial revision.
It was agreed some time ago that the new process would be rolled out to enable ‘off-year’ reviews to take place for the first time in 2021. But the question of which products should become subject to such a review has, to date, remained open. Furthermore, the impact of the coronavirus/COVID-19 crisis has entrenched divisions between manufacturers (and certain elements within the government), who favour a postponement or delay of the planned 2021 implementation date, and the health and finance ministries, which are mindful of the potential savings to be gained from implementing the new system sooner rather than later.
在2020年9月中旬任命Suga总理,在以健康理由辞职后,取代了他的前任Shinzo Abe,这进一步增加了有关是否以及如何进行的辩论。lol买外围用什么软件根据日本制药公司的说法,苏加在他对日本饮食(议会)的第一次政策演讲中强调,他的政府将寻求“纠正效率低下和不公平”,在这种情况下,它将“努力实现年度NHI价格修订”。
But in response, the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) and the Japan Pharmaceutical Manufacturers Association (JPMA) have reiterated their call for the government to adopt a “cautious approach”. The associations argue that the impact of the pandemic has made it more difficult for Korosho to conduct an accurate market price survey ahead of the planned 2021 price revision, since price negotiations between many wholesalers and healthcare providers have yet to conclude, making it more difficult to gauge the actual prices of products in the market. Furthermore, they argue, the planned price revisions would serve as an unnecessary distraction at a time when healthcare providers and drug manufacturers are seeking to work more closely together to ensure that the stable supply of medicines can be maintained.
就批发商而言,批发商担心受到COVID-19的大流行影响的医疗机构可能会比往常寻求更深层次的毒品购买折扣(据报道,医院在某些情况下要求过度折扣,因为在大流行期间的收入恶化,)。此外,由于与共同相关的限制,销售代表的谈判也受到了打击。结果,在这个关键时期,市场价格调查的发现可能会导致明年更深的降价,批发商警告说。
Korosho, however, faces opposing pressure from other quarters. The MOF in early October 2020 advised that the proposed scope of products to be subject to an ‘off-year’ review should be broadened, suggesting that the health ministry should look at the overall (actual monetary value) difference between a product’s NHI reimbursement price and its actual market price, rather than just the percentage difference (yakkasa), when deciding whether a drug’s price should be adjusted. The MOF reportedly argues that focusing only on the yakkasa would mean that the vast majority of products subject to an ‘off-year’ revision would be generic drugs, rather than more expensive innovative medicines.
Notably, IQVIA’s Market Prognosis, which provides five-year forecasts of pharmaceutical sales in Japan, assumes that the off-year price revisions will indeed go ahead from April 2021 onwards, but that the impact on the total market value will be less significant than the full biennial revisions. Estimated price impacts are as follows:- Biennial price revisions (even years 2022 and 2024): -5.3 to -6.3%
- “下年”价格修订(奇数2021和2023):-4.0至-5.0%
Koroshohas said that it will make a decision on whether to go ahead with the ‘off-year’ revision only once the market price survey has been completed. With the survey now reported to be under way (as at November 2020), this means it will likely be late 2020 or early 2021 before the Ministry makes a final call, and there remains little clarity on how COVID-19 effects will be taken into account. This potentially gives manufacturers just weeks to prepare if the revised prices are to be implemented on 1 April 2021 as expected. And although (echoing drug makers’ concerns) Korosho is reportedly worried about the reliability of the survey, the Prime Minister’s backing could ultimately prove decisive.
January 2021 Update from PPR and Market Prognosis Teams:
Since IQVIA published the above analysis in December 2020, the Japanese authorities have continued to work toward implementation of the first ever ‘off-year’ NHI price revision in April 2021.
在这方面有许多关键里程碑:- In early December 2020,Korosho宣布了2020年9月开始的市场价格调查的结果(见上文)。根据新闻报道,调查发现平均yakkasa(ie the difference between the NHI reimbursement price and the actual market price) across all drugs was around 8.0%. This was somewhat lower than expected; stakeholders had predicted that theyakkasacould be above 9.0% as a result of increased discount pressure from pharmacies and wholesalers experiencing turnover problems due to the economic impact of the ongoing pandemic.
- Following publication of the survey results,Koroshoannounced in mid-December 2020 the planned scope of products to be covered by the 2021 ‘off-year’ price adjustment. The scope is to be based on theyakkasa, with price adjustments to be applied in April 2021 to all products found to have ayakkasaof more than 5.0%. Initial calculations by the Ministry suggest that this means that around 70% of all products included on the NHI reimbursement list as at September 2020 will be subject to NHI price adjustments in 2021.
- Koroshosubsequently provided further detail on how price adjustments for individual products will be calculated. Notably, this will differ in some key respects from the methodology used for biennial (‘on-year’) NHI price adjustments. When implementing price adjustments based on actual market prices,Koroshonormally allows a variation of up to 2.0% (known as the price adjustment range). Applying this to the 8.0% figure would mean that, if implemented, the average NHI price reduction in April 2021 would be around 6.0%. Instead, however, in April 2021 the price adjustment range is to be set at 2.8% -meaning that the average price reduction under this mechanism will be around 5.2%(although the final price adjustment for each individual product will also depend on other factors, such as the implementation of the price premium for the development of new drugs, and price increases that may be permitted for certain “essential” drugs).
Announcing its fiscal year (FY) 2021 (ie 1 April 2021 to 31 March 2022) budget on 21 December 2020, the government is reported to have stated that it expects the implementation of the “off-year” price revisions to generate savings of Yen431.5 billion for the health system in FY2021. This aligns with the latest Market Prognosis forecast that predicts a -4.0% to -5.0% impact of 2021 price adjustments on total market value.
IQVIA Pharma定价和报销(PPR)利用了数十年的市场访问空间经验,为您带来了定价和报销方面的最新全球发展。通过访问IQVIA的本地办事处网络以及政府和行业内部的广泛联系,PPR服务提供了及时的新闻和文章,以及全球P&R法规的全面指南。
IQVIA市场预后是一个战略市场预测出版物,可为影响当地药品和医疗保健行业的关键问题提供无与伦比的见解。王者荣耀kpl外围投注lol买外围用什么软件市场预后报告系列提供了49个深入的国家预测。